MAPK3 and RASopathy: Thus, our targeting approach may also facilitate the application of the Raf/MEK/ERK1/2 cascade inhibitors for long-term therapy, which would be needed for the therapy of heart failure and rare genetic syndromes like RASopathies, but also with respect to chronic side effects of cancer treatment1,13,37,47,59–63.